BMRN FY2025 SEC EDGAR DEF 14A #41 of 168 in industry

Biomarin Pharmaceutical Inc CEO pay ratio

The CEO earned $21.9M in FY2025 against median worker pay of $201,036 · Chemicals & Pharmaceuticals.

Chemicals & Pharmaceuticals peers All rankings
State
DE
Filing date
2026-04-21
Industry
Chemicals & Pharmaceuticals
Industry rank
#41/168

Data updated August 2026

Subscribe to Biomarin Pharmaceutical Inc CEO pay filing updates (RSS)

CEO-to-worker pay ratio
109:1
Moderate (Scale: 0–1000:1)
CEO pay
$21.9M
Median worker
$201,036

Answer first

Biomarin Pharmaceutical Inc's FY2025 CEO total of $21.9M ranks #145 of 1,423 complete filings; its 109:1 pay ratio ranks #597. Dollar rank is not ratio rank.

According to the same FY2025 complete-filing cohort used on the rankings boards (CEO total, median worker, and ratio all present). Median worker pay is $201,036. Industry placement uses the FY2025 SIC-28 peer cohort (# 41 of 168, 76th percentile - top quartile of industry peers by pay ratio). Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.

Dollar rank
#145
$21.9M of 1,423 FY2025
Ratio rank
#597
109:1 of 1,423
Industry pct
76th
top quartile of industry peers by pay ratio

How Biomarin Pharmaceutical Inc ranks nationally

Biomarin Pharmaceutical Inc CEO pay vs. every FY2025 complete filing

Total CEO compensation, the full national distribution, this company marked

$21,927,563 Top 10% higher than 90% of 1,423 companies

$0–$2,500,000: 304 companies (21%). Below this entry. $2,500,000–$5,000,000: 182 companies (13%). Below this entry. $5,000,000–$7,500,000: 208 companies (15%). Below this entry. $7,500,000–$10,000,000: 192 companies (13%). Below this entry. $10,000,000–$12,500,000: 139 companies (10%). Below this entry. $12,500,000–$15,000,000: 91 companies (6%). Below this entry. $15,000,000–$17,500,000: 88 companies (6%). Below this entry. $17,500,000–$20,000,000: 54 companies (4%). Below this entry. $20,000,000–$22,500,000: 24 companies (2%). This entry sits in this band. $22,500,000–$25,000,000: 34 companies (2%). Above this entry. $25,000,000–$27,500,000: 24 companies (2%). Above this entry. $27,500,000–$30,000,000: 16 companies (1%). Above this entry. $30,000,000–$32,500,000: 10 companies (1%). Above this entry. $32,500,000–$35,000,000: 7 companies (0%). Above this entry. $35,000,000–$37,500,000: 9 companies (1%). Above this entry. $37,500,000–$40,000,000: 6 companies (0%). Above this entry. $40,000,000–$42,500,000: 1 companies (0%). Above this entry. $42,500,000–$45,000,000: 1 companies (0%). Above this entry. $45,000,000–$47,500,000: 6 companies (0%). Above this entry. $47,500,000–$50,000,000: 27 companies (2%). Above this entry. This company $0 $50M+ every complete-filing company, bucketed by value

Each bar is a $2500K-wide band; taller bars hold more companies. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source SEC DEF 14A Section 953(b) disclosures, PlainCEOPay extract · FY2025

Biomarin Pharmaceutical Inc vs. Chemicals & Pharmaceuticals peers

CEO total pay ($21.9M) against pay ratio (109:1) for Biomarin Pharmaceutical Inc (marked) and its 4 closest same-industry peers, against the Chemicals & Pharmaceuticals industry median on both axes.

Pay + gap both highContained pay, wide gapHigh pay, contained gapBelow peer norms on both3092907.18475861.013858815.019241768.924624722.938.4:158.2:178:197.8:1117.6:1CEO total payPay ratio (CEO : median worker)Biomarin Pharmaceutical Inc, CEO total pay: 21927563 · Pay ratio (CEO : median worker): 109:1Biomarin Pharmaceutical IncCronos Group Inc., CEO total pay: 4071626 · Pay ratio (CEO : median worker): 112:1Cronos Group Inc.Biogen Inc., CEO total pay: 23646004 · Pay ratio (CEO : median worker): 113:1Biogen Inc.Ani Pharmaceuticals Inc, CEO total pay: 10254756 · Pay ratio (CEO : median worker): 114:1Ani Pharmaceuticals IncPerimeter Solutions, Inc., CEO total pay: 8062080 · Pay ratio (CEO : median worker): 114:1Perimeter Solutions, Inc.
Biomarin Pharmaceutical Inc vs. Chemicals & Pharmaceuticals peers, plotted against the industry's $7.9M median CEO total and 42:1 median pay ratio.

Ratio bands among Chemicals & Pharmaceuticals peers

Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.

CEO Compensation Breakdown, FY2025

A component-level pay breakdown is not reported in Biomarin Pharmaceutical Inc's structured SEC pay-ratio disclosure. See our methodology →

Filing-year trail · Biomarin Pharmaceutical Inc

Complete DEF 14A pay-ratio filings for this CIK across FY2021–2025. Year-over-year deltas compare adjacent filing years only; incomplete dollar rows are omitted (same completeness gate as the hero figures).

Latest ratio
109:1
FY2025
vs prior FY
+25:1
from FY2024 84:1
CEO $ YoY
+48%
$21.9M latest
Filings shown
5
FY2021–2025
Biomarin Pharmaceutical Inc CEO total compensation, median worker pay, and pay ratio by fiscal year from SEC EDGAR DEF 14A.
FY CEO pay Δ pay Median worker Pay ratio Δ ratio
2021 $18.3M - $175,523 104:1 -
2022 $18.4M +0.5% $193,557 95:1 -9:1
2023 $22.0M +20% $191,101 116:1 +21:1
2024 $14.9M -32% $176,090 84:1 -32:1
2025 $21.9M +48% $201,036 109:1 +25:1

Source: SEC EDGAR DEF 14A pay-ratio disclosures for CIK 1048477, FY2021–2025. Adjacent-year deltas only.

Industry Comparison - Chemicals & Pharmaceuticals

This Company's Ratio
109:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$21.9M
Companies in Industry
168
vs. Industry Median
Above
#41 of 168 by pay ratio in this industry View all companies in Chemicals & Pharmaceuticals →

Biomarin Pharmaceutical Inc: MID · PEAK pay ratio

Biomarin Pharmaceutical Inc's FY2025 ratio 109:1 ranks #41 of 168 Chemicals & Pharmaceuticals filers (76th percentile). the CEO earned 109× the median employee ($201,036) in FY2025.

Median employee $201,036 (ELITE-MED); MID · PEAK stamps put about 109 median-wage years per CEO year.

CEO Total Pay

$21.9M

FY2025 Summary Compensation, well above median

Pay Ratio

109:1

Near industry median

Biomarin Pharmaceutical Inc in the higher Chemicals & Pharmaceuticals third

Biomarin Pharmaceutical Inc's FY2025 ratio 109:1 ranks #41 of 168 Chemicals & Pharmaceuticals filers (76th percentile). The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Biomarin Pharmaceutical Inc's $21.9M CEO total is above the $7.9M industry median CEO pay.

Dollar rank #145 and ratio rank #597 split - treat 109:1 as a disclosure, not a fairness score. Open Chemicals & Pharmaceuticals peers.

Key Data, FY2025

Total Compensation
$21.9M
Median Employee Pay
$201,036
Pay Ratio
109:1
Filing Date
2026-04-21

Company Info

Ticker
BMRN
CIK
1048477
Industry
Chemicals & Pharmaceuticals
SIC Code
2834
State
DE
View SEC filings →
SEC EDGAR DEF 14A for CIK 1048477, FY2025. Informational only, not investment advice. Verify on EDGAR.

Read our methodology - how this data is sourced, computed, and verified. Biomarin Pharmaceutical Inc's FY2025 ratio 109:1 ranks #41 of 168 Chemicals & Pharmaceuticals filers (76th percentile).

Read with Biomarin Pharmaceutical Inc

ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MID · PEAK · ELITE-MED.

Bristol Myers Squibb Co · PEAK

ABS(ceo_total_comp) peer at $21.9M (Δ $26K lighter vs Biomarin Pharmaceutical Inc); MID · ELITE-MED vs this page's MID · PEAK · ELITE-MED.
Chefs' Warehouse, Inc. · PEAK

ABS(ceo_total_comp) peer at $22.0M (Δ $34K heavier vs Biomarin Pharmaceutical Inc); FLOOR · PAR-MED vs this page's MID · PEAK · ELITE-MED.
Nrg Energy, Inc. · PEAK

ABS(ceo_total_comp) peer at $21.8M (Δ $128K lighter vs Biomarin Pharmaceutical Inc); STEEP · HIGH-MED vs this page's MID · PEAK · ELITE-MED.
Linde PLC · PEAK

ABS(ceo_total_comp) peer at $21.8M (Δ $150K lighter vs Biomarin Pharmaceutical Inc); HIGH · PAR-MED vs this page's MID · PEAK · ELITE-MED.
Cronos Group Inc. (SIC 28 pole)

Cronos Group Inc. stamps MID · MID$ nearest in-SIC by ABS(pay_ratio) to Biomarin Pharmaceutical Inc's MID filing.
National dual ranks · #145/#597

Biomarin Pharmaceutical Inc's FY2025 package sits #145 by CEO dollars and #597 by ratio under PEAK · MID.
Comp structure · PEAK

Biomarin Pharmaceutical Inc's PEAK CEO total is equity-sensitive - read what grant-date fair value does and does not mean.
Data sourced from SEC EDGAR DEF 14A for Biomarin Pharmaceutical Inc (CIK 1048477), FY2025. See our methodology. Aggregated by PlainCEOPay as of August 2026.

Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.